Tirzepatide for Sleep Apnea: FDA Approval and SURMOUNT-OSA Trial Results

In December 2024, the FDA approved a new indication for tirzepatide, making it the first medication in history approved specifically to reduce the severity of obstructive sleep apnea (OSA) in adults with obesity. This was not a secondary finding from a weight loss trial. It was a dedicated FDA indication, supported by data from the largest randomized controlled drug trial ever conducted for OSA.

If you have obstructive sleep apnea and you are also managing your weight, or if you have been considering a GLP-1 medication and want to understand what the research actually shows for sleep, this article covers the trial design, the results, the approval, and what it means in practice.

*Compounded tirzepatide is not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical trial data discussed here was gathered using FDA-approved tirzepatide (Zepbound). Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

The FDA Approval: What Happened and Why It Matters

In December 2024, the FDA approved tirzepatide (Zepbound) for a new indication: as an adjunct to a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity and moderate-to-severe obstructive sleep apnea.

This made tirzepatide the first pharmaceutical agent to receive an FDA indication specifically for treating OSA. Prior to this approval, no drug had ever been approved to directly reduce sleep apnea severity. Treatments existed for managing the condition, primarily continuous positive airway pressure (CPAP) therapy, but no medication had a label that said: this reduces the number of times you stop breathing per hour.

The approval was based on the SURMOUNT-OSA clinical trial program, a phase 3 placebo-controlled randomized trial that enrolled more than 460 adults across two parallel studies. The trial measured apnea-hypopnea index (AHI) as its primary endpoint: the number of breathing events (apneas and hypopneas) per hour of sleep.

That choice of primary endpoint matters. AHI is the gold-standard objective measure of OSA severity, not a surrogate. A reduction in AHI is a direct measure of reduced sleep-disordered breathing events, not an indirect marker.

---

Understanding Obstructive Sleep Apnea

Obstructive sleep apnea occurs when the muscles and soft tissue in your upper airway relax excessively during sleep, causing partial or complete airway collapse. When your airway closes, you stop breathing momentarily, your blood oxygen level drops, and your brain sends a signal to arouse you just enough to restore airflow. This cycle can repeat dozens or hundreds of times per night.

Most people with OSA never fully wake up during these events, but the micro-arousals fragment sleep architecture. The result is poor-quality sleep, even if you believe you slept a full eight hours: daytime fatigue, impaired concentration, morning headaches, mood changes, and elevated risk for cardiovascular complications including hypertension, atrial fibrillation, and stroke.

OSA is classified by AHI:

• Mild OSA: 5 to 14 events per hour
• Moderate OSA: 15 to 29 events per hour
• Severe OSA: 30 or more events per hour

Obesity is one of the strongest modifiable risk factors for OSA. Fat deposits around the neck and pharynx narrow the upper airway. Increased abdominal fat reduces chest wall compliance and functional residual capacity, making airway mechanics worse during sleep. A systematic review in *Sleep Medicine Reviews* (PMID: 27568340) found OSA prevalence of 9 to 38% in the general population, with rates rising sharply in people with obesity.

This is the mechanism through which weight management and OSA are directly connected.

---

SURMOUNT-OSA: Trial Design

The SURMOUNT-OSA trial (PMID: 38912654), published in the *New England Journal of Medicine* in 2024, enrolled adults with moderate-to-severe obstructive sleep apnea (AHI of 15 or more events per hour) and obesity (BMI of 30 or above). The trial was structured as two parallel, independent randomized controlled studies.

Trial 1 enrolled participants who were not using CPAP therapy. These were adults whose sleep apnea was either untreated, or who had declined, stopped, or failed CPAP.

Trial 2 enrolled participants who were already on CPAP therapy and wished to continue it throughout the study.

In both trials, participants were randomly assigned 1:1 to receive tirzepatide or placebo, once weekly, subcutaneously. Dosing followed the standard titration schedule: starting at 2.5 mg weekly and escalating every four weeks toward the maximum tolerated dose of 10 mg or 15 mg. The treatment period was 52 weeks, followed by a 12-week follow-up off medication.

Primary endpoint: change from baseline in AHI (events per hour of sleep) at week 52, measured by home sleep apnea testing.

Pre-specified secondary endpoints included:

• Percentage of participants achieving AHI below 5 (disease resolution)
• Percentage achieving AHI below 15 (mild or resolved)
• Hypoxic burden (oxygen desaturation index, ODI, and time with SpO2 below 90%)
• Patient-reported sleep disturbance (PROMIS Sleep Disturbance 8a scale)
• Systolic blood pressure
• High-sensitivity C-reactive protein (hsCRP)
• Body weight

---

Primary Results: AHI Reduction

In Trial 1 (participants not using CPAP), tirzepatide reduced AHI by a mean of 25.3 events per hour from baseline, compared to 5.3 events per hour with placebo. The least-squares mean treatment difference was -20.1 events per hour.

In Trial 2 (participants using CPAP), tirzepatide reduced AHI by a mean of 29.3 events per hour from baseline, compared to 5.5 events per hour with placebo. The treatment difference was -23.8 events per hour.

Both results were highly statistically significant (p < 0.0001 in each trial). These reductions represent a roughly 60 to 65 percent mean decrease in hourly breathing events.

To put those numbers in clinical context: a participant starting with an AHI of 40 events per hour (severe OSA) who achieved a 25-event reduction would move from severe to mild-to-moderate territory. Many participants moved entirely out of the OSA range.

---

Who Reached Disease Resolution?

One of the most striking secondary findings was the proportion of participants whose OSA resolved clinically.

In Trial 1, 42.5% of tirzepatide participants reached an AHI below 5 at week 52, meeting standard criteria for resolution of OSA. In the placebo group, 15.7% reached this threshold.

In Trial 2 (with CPAP), 49.9% of tirzepatide participants reached AHI below 5, compared to 24.0% with placebo.

When the threshold was expanded to AHI below 15 (mild or resolved), the tirzepatide advantage was more pronounced still. In Trial 1, approximately 80% of tirzepatide participants reached this level, compared to roughly 35% on placebo.

These are not modest improvements in a chronic condition. For a substantial proportion of participants, OSA as a clinical diagnosis was no longer present at the end of the study.

*Clinical trial data referenced above was gathered using FDA-approved tirzepatide formulations. Compounded tirzepatide is not FDA-approved and has not been studied in dedicated sleep apnea trials.*

---

Secondary Outcomes: Beyond AHI

Breathing events per hour are the headline number, but the SURMOUNT-OSA secondary endpoints tell a fuller story about what improved.

Hypoxic burden: Tirzepatide significantly reduced the oxygen desaturation index and time spent with blood oxygen saturation below 90% per night. These oxygen-related measures reflect the downstream cardiovascular stress that OSA imposes. The longer your oxygen level stays low during sleep, the greater the cardiovascular strain. Improving AHI without improving hypoxic burden would leave a key part of the disease mechanism unaddressed. Tirzepatide improved both.

Systolic blood pressure: Tirzepatide reduced systolic blood pressure significantly versus placebo. This is consistent with what is seen in weight loss trials more broadly, but in the context of OSA treatment it is particularly relevant: OSA-related overnight hypoxemia is itself a driver of hypertension, and reducing both the sleep-disordered breathing and blood pressure simultaneously addresses compounding risk.

Inflammation (hsCRP): High-sensitivity C-reactive protein, a marker of systemic inflammation, was significantly lower in the tirzepatide groups than placebo. OSA is associated with chronic low-grade inflammation, partly through intermittent nocturnal hypoxemia and sleep fragmentation. The hsCRP reductions observed in SURMOUNT-OSA are consistent with the inflammatory reduction seen in SURMOUNT-1 and other tirzepatide weight loss trials.

Patient-reported sleep quality: Using the PROMIS Sleep Disturbance 8a instrument, participants in the tirzepatide groups reported significantly greater improvements in sleep disturbance compared to placebo. Objective AHI improvement and subjective sleep quality improvement were aligned, which is not always the case in sleep intervention research.

---

How Much of the Effect Is from Weight Loss?

The SURMOUNT-OSA trial was not designed to isolate weight loss as a mechanism. Tirzepatide produces substantial weight loss, and weight loss reduces OSA severity. That is well established. In the trial, tirzepatide-treated participants lost approximately 18 to 20 percent of body weight over 52 weeks, consistent with SURMOUNT-1 outcomes.

But the question researchers have been exploring is whether GLP-1 and GIP receptor activation might have effects on breathing regulation beyond what weight loss alone predicts. Animal studies and early human mechanistic data suggest that GLP-1 receptors are expressed in the brainstem nuclei that regulate respiratory pattern, and that GLP-1 receptor activation may directly modulate respiratory drive during sleep. GIP receptors are found in adipose tissue and central nervous system circuits involved in energy regulation.

Whether these mechanisms contribute meaningfully to the OSA reduction seen in SURMOUNT-OSA, or whether the effect is substantially driven by the 18-20% weight loss, has not been definitively resolved. The mediation analysis from the trial suggests weight loss accounts for a large portion of the AHI effect, but not all of it.

For practical purposes, this distinction matters less to you as a patient than the outcome: in a well-designed 52-week randomized trial, tirzepatide significantly and substantially reduced sleep apnea severity by multiple objective and patient-reported measures.

---

What the FDA Approval Means Practically

The December 2024 FDA approval for tirzepatide in OSA applies specifically to adults with moderate-to-severe OSA (consistent with the SURMOUNT-OSA eligibility criteria: AHI of 15 or more) and obesity (BMI of 30 or above).

A few practical implications:

It is a separate indication from weight loss. Tirzepatide's original FDA approvals were for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). The OSA indication is an additional approved use for the Zepbound label, not a modification of the existing obesity indication.

It does not replace CPAP. The FDA label and the clinical guidelines are clear: tirzepatide is indicated as an adjunct to a reduced-calorie diet and increased physical activity. It is not positioned as a CPAP substitute. For people with severe OSA and significant cardiovascular risk, CPAP remains the most reliable acute intervention.

Insurance and access: As with any new indication, coverage policies vary by insurer and plan. Checking with your insurer whether the OSA indication changes your coverage tier or prior authorization pathway is worth doing if access to Zepbound has been a barrier.

Compounded tirzepatide: The FDA indication applies to Zepbound (FDA-approved tirzepatide). Compounded tirzepatide is not FDA-approved, including for OSA treatment. If you are already using compounded tirzepatide for weight management and your provider has identified moderate-to-severe OSA as a concurrent diagnosis, discussing whether the Zepbound indication is relevant to your situation is appropriate. Your provider will guide that decision.

---

Safety and Tolerability in SURMOUNT-OSA

The safety profile in SURMOUNT-OSA was consistent with tirzepatide's established profile across other SURMOUNT trials. The most common adverse events were gastrointestinal: nausea, diarrhea, vomiting, and constipation. These occurred more frequently during the titration phase and generally decreased in intensity and frequency as participants reached their maintenance dose.

Serious adverse events occurred at similar rates between tirzepatide and placebo groups overall. Treatment discontinuation due to adverse events was low, in line with other phase 3 SURMOUNT data.

Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or in people with MEN2 (multiple endocrine neoplasia syndrome type 2). As with all GLP-1 medications, the prescribing provider will review your complete medical history and current medications before recommending tirzepatide.

---

What This Means for You

If you have moderate-to-severe obstructive sleep apnea and obesity, you are now in a situation where there is robust, phase 3 randomized clinical trial evidence supporting a pharmacological approach to reducing your sleep apnea severity, not just managing its downstream symptoms with a device.

This does not mean tirzepatide is the right choice for every person with OSA and obesity. Factors that matter include cardiovascular risk profile, CPAP tolerance history, other medications, and overall metabolic health. A provider who reviews your complete clinical picture is the right person to help you weigh these options.

What the SURMOUNT-OSA trial and the subsequent FDA approval have established is that tirzepatide significantly reduces AHI, improves hypoxic burden, reduces systemic inflammation, lowers blood pressure, and improves patient-reported sleep quality in adults with obesity and moderate-to-severe OSA. Nearly half of participants in the trial no longer met criteria for OSA at the end of 52 weeks.

That is a meaningful outcome for a condition that has historically been managed rather than resolved.

---

Accessing Compounded Tirzepatide

Independently licensed healthcare providers in Prescriva's affiliated network evaluate whether compounded tirzepatide may be appropriate based on individual health history. If a provider determines a compounded formulation is clinically appropriate, prescriptions are filled by state-licensed 503A compounding pharmacies operating under state pharmacy board oversight and USP compounding standards.

Compounded tirzepatide is not FDA-approved and is not the same as Zepbound. The FDA indication for tirzepatide in sleep apnea applies to the branded FDA-approved formulation only.

If you are interested in exploring whether a GLP-1 program may be appropriate for your health goals, [begin your eligibility assessment](/get-started) to connect with a licensed provider.

---

The Bottom Line

In December 2024, tirzepatide became the first drug in history to receive FDA approval specifically for reducing the severity of obstructive sleep apnea in adults with obesity. The approval was based on the SURMOUNT-OSA trial (PMID: 38912654), which showed mean AHI reductions of 25 to 29 events per hour versus 5 to 6 with placebo, along with significant improvements in hypoxic burden, blood pressure, inflammation, and patient-reported sleep quality.

If you have been diagnosed with moderate-to-severe OSA and are also managing your weight, the evidence base for discussing tirzepatide with your provider has never been stronger.

*This article is for informational and educational purposes only. It does not constitute medical advice. Compounded medications are not FDA-approved. Clinical trial data cited here reflects research conducted with FDA-approved tirzepatide formulations. Individual results vary. Consult your licensed healthcare provider before making any changes to your treatment plan. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.*

---

Sources

1. Malhotra A et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity." *New England Journal of Medicine*. 2024. PMID: 38912654.

1. Senaratna CV et al. "Prevalence of obstructive sleep apnea in the general population: A systematic review." *Sleep Medicine Reviews*. 2017. PMID: 27568340.

1. Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." *New England Journal of Medicine*. 2022. PMID: 35658024.

1. Le KDR et al. "The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review." *Pharmacy (Basel)*. 2024. PMID: 38251405.